Compare GTX & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GTX | EWTX |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.3B |
| IPO Year | 2021 | 2021 |
| Metric | GTX | EWTX |
|---|---|---|
| Price | $20.65 | $30.45 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | $20.40 | ★ $39.00 |
| AVG Volume (30 Days) | ★ 1.7M | 899.6K |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.56% | N/A |
| EPS Growth | ★ 20.63 | N/A |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $3,584,000,000.00 | N/A |
| Revenue This Year | $4.16 | N/A |
| Revenue Next Year | $3.27 | N/A |
| P/E Ratio | $13.47 | ★ N/A |
| Revenue Growth | ★ 3.14 | N/A |
| 52 Week Low | $9.58 | $12.31 |
| 52 Week High | $21.42 | $35.00 |
| Indicator | GTX | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 62.10 | 43.33 |
| Support Level | $17.17 | $28.72 |
| Resistance Level | $20.53 | $31.28 |
| Average True Range (ATR) | 0.55 | 1.52 |
| MACD | 0.11 | -0.44 |
| Stochastic Oscillator | 68.61 | 4.93 |
Garrett Motion Inc designs, manufactures and sells engineered turbocharger and electric-boosting technologies for light and commercial vehicle original equipment manufacturers (OEMs). The company is a technology leader with expertise in delivering products across gasoline, diesel, natural gas and electrified powertrains. The company also sells its technologies in the aftermarket through its distribution network. The company derives maximum of its revenue from Gas and geographically from Europe.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.